BioSpace

BridgeBio gears up for rare muscular dystrophy launch with FDA approval in sight

If approved, BridgeBio Pharma’s BBP-418—which, according to one Jefferies analyst, boasts “pretty darn compelling” data—would be the first therapy for limb-girdle muscular dystrophy. The FDA has an action date of Nov. 27.

By BioSpace

1 min read
BridgeBio gears up for rare muscular dystrophy launch with FDA approval in sight
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights